ReviewJournal of computer-aided molecular design2026
Machine learning for discovering anticancer compounds from plants and elucidating their mechanisms.
Review in Journal of computer-aided molecular design, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Plants are important sources of bioactive compounds with demonstrated anticancer and cancer-preventive properties. However, traditional methods for discovering and deciphering the mechanisms of these compounds are often slow and labor-intensive. The integration of machine learning (ML) provides a computational approach for bioactivity prediction, candidate prioritization, and mechanistic hypothesis generation. Algorithms including support vector machines (SVM) and graph neural networks (GNN) are increasingly employed to support multiple stages from compound screening to experimentally guided mechanistic investigation. Despite these advances, challenges such as data heterogeneity and structural complexity of natural products remain. This review systematically outlines the natural anticancer compounds derived from plants, summarizes the application of machine learning in bioactivity prediction, candidate prioritization, and mechanistic investigation, compares functional-group prevalence and co-occurrence patterns in plant-derived anticancer compounds and FDA-approved anticancer drugs, and identifies current challenges along with future directions for AI-assisted discovery in this field.
Indexed as
Identifiers
42821033What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.